TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15040558

Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ) 15 mg/kg in a single oral dose
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQ-AS) combination therapy (MQ 15 mg/kg plus AS 4 mg/kg daily for 3 days)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Mefloquine (MQ) alone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (MQ-AS) combination therapy
Number of subjects: 143
Study: 14687445

Group type: EXPERIMENTAL
Intervention: Mirtazapine orally disintegrating tablets (15-45 mg/day)
Number of subjects: 119
Study: 10468082

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.02 U/kg/day for 6 months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 10
Study: 8586897

Group type: EXPERIMENTAL
Intervention: Water bath hyperthermia (delivered biweekly for 8 weeks)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Water bath hyperthermia (increased frequency to alternate days for some patients)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Water bath hyperthermia
Number of subjects: 7
Study: 1972381

Group type: EXPERIMENTAL
Intervention: Estazolam 4 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Estazolam 6 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg/kg
Number of subjects: 60
Study: 537956

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0
Study: 31518433

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 19
Study: 28683837

Group type: EXPERIMENTAL
Intervention: Navigation system (IMACTIS-CT®)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional CT guidance
Number of subjects: 500
Study: 26409213

Group type: EXPERIMENTAL
Intervention: Evaluative conditioning procedure pairing unhealthy food with negative affect
Number of subjects: 134

Group type: COMPARATOR
Intervention: Evaluative conditioning procedure pairing unhealthy food with positive affect
Number of subjects: 134
Study: 23410208

Group type: EXPERIMENTAL
Intervention: PD with pylorus preservation
Number of subjects: 89

Group type: COMPARATOR
Intervention: PD with pylorus resection and complete stomach preservation
Number of subjects: 89
Study: 20619394

Group type: EXPERIMENTAL
Intervention: Synbiotic therapy (Bifidobacterium breve, Lactobacillus casei, and galactooligosaccharides) for 2 days preoperatively and 2 weeks postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group without synbiotic therapy
Number of subjects: 50
Study: 19596057

Group type: EXPERIMENTAL
Intervention: PXM generic formulation (LaborMed Pharma, Romania)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Feldene (Pfizer, USA)
Number of subjects: 24
Study: 17763612

Group type: EXPERIMENTAL
Intervention: OTC moisturizing cream
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium sulfacetamide 10% lotion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Jar clindamycin 1%/benzoyl peroxide 5% gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tube clindamycin 1%/benzoyl peroxide 5% gel
Number of subjects: 36
Study: 15115516

Group type: EXPERIMENTAL
Intervention: Pulsed oral terbinafine (standard dose)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Pulsed oral terbinafine (double dose)
Number of subjects: 42
Study: 11435052

Group type: EXPERIMENTAL
Intervention: Midazolam (10 microg kg(‐1))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flumazenil (5 microg kg(‐1))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9608378

Group type: EXPERIMENTAL
Intervention: Neck support pillows
Number of subjects: 55
Study: 30862374

Group type: EXPERIMENTAL
Intervention: Trial disinfectant (persistent disinfectant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dilutable quaternary ammonium agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disinfectant with ethanol and quaternary ammonium
Number of subjects: 0
Study: 29424155

Group type: EXPERIMENTAL
Intervention: Joint mobilization
Number of subjects: 67

Group type: COMPARATOR
Intervention: Routine exercise
Number of subjects: 67
Study: 25404551

Group type: EXPERIMENTAL
Intervention: Peritonsillar lornoxicam (8 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (bilateral peritonsillar saline infiltration)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 68
Study: 23313606

Group type: EXPERIMENTAL
Intervention: Daytime fluctuations in skin temperature after total sleep deprivation
Number of subjects: 8
Study: 19463127

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (stable dose) (n=52)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Atorvastatin titration from 10 to 80 mg/day (n=50)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Common therapy including lipid lowering drugs (n=46)
Number of subjects: 148
Study: 17380211

Group type: EXPERIMENTAL
Intervention: Lumiracoxib (100-400 mg once a day for chronic pain; 400 mg/day for acute pain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lumiracoxib
Number of subjects: 0
Study: 15262691

Group type: EXPERIMENTAL
Intervention: Topical 0.5% fluorouracil
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil plus cryosurgery
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vehicle plus cryosurgery
Number of subjects: 144
Study: 11795749

Group type: EXPERIMENTAL
Intervention: Cervical cages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allograft or autograft fusion techniques
Number of subjects: 0
Study: 9892520

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 19185

Group type: COMPARATOR
Intervention: Aspirin (325 mg daily)
Number of subjects: 19185
Study: 7612056

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (4.4 mg as tablet, administered b.i.d. on days 4 to 10, single dose on days 1 and 11)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride (4.4 mg as tablet)
Number of subjects: 14
Study: 2562605

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol (50 micrograms/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ethinyl oestradiol (20 micrograms/day)
Number of subjects: 25
Study: 389037

Group type: EXPERIMENTAL
Intervention: Continuous Negative Pressure (CNP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (CPAP)
Number of subjects: 36
Study: 31637467

Group type: EXPERIMENTAL
Intervention: AquaCelle® fish oil formulation (SEDDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (unformulated fish oil EE)
Number of subjects: 0
Study: 31153838

Group type: COMPARATOR
Intervention: Best Medical Therapy (BMT)
Number of subjects: 2983

Group type: EXPERIMENTAL
Intervention: PTA plus SET
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Supervised Exercise Therapy (SET)
Number of subjects: 2983

Group type: COMPARATOR
Intervention: Percutaneous Angioplasty (PTA)
Number of subjects: 2983
Study: 28433451

Group type: EXPERIMENTAL
Intervention: Zimmer Natural Nail (ZNN)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Proximal Femoral Nail Antirotation II (PFNA II)
Number of subjects: 353
Study: 25586331

Group type: EXPERIMENTAL
Intervention: Fibrocaps (FC-002 US)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fibrocaps (FC-002 NL)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Fibrocaps
Number of subjects: 126
Study: 22805174

Group type: EXPERIMENTAL
Intervention: Treatment Interruption (TI)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Continuous Treatment (CT)
Number of subjects: 106
Study: 20864621

Group type: EXPERIMENTAL
Intervention: Single doses of eliglustat tartrate ≤ 20 mg/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Multiple doses of eliglustat tartrate ≤ 200 mg bid
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Single doses ≥ 10 mg/kg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Single-dose pharmacokinetics
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Multiple-dose pharmacokinetics
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Food effect on eliglustat tartrate
Number of subjects: 99
Study: 19282098

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone at 2.5 mg/day (n=4)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone at 5.0 mg/day (n=5)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone at 7.5 mg/day (n=5)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (all doses)
Number of subjects: 15
Study: 17451575

Group type: COMPARATOR
Intervention: Hyaluronic acid gel implantation alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel followed by laser/RF/IPL treatment
Number of subjects: 36
Study: 15367185

Group type: COMPARATOR
Intervention: Prototype E6500 (s1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prototype E6500 (s2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prototype E8000
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prototype E6500 (s3)
Number of subjects: 24
Study: 11137097

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 10345151

Group type: EXPERIMENTAL
Intervention: Diet/exercise/supplement group (n = 56)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Diet/exercise/placebo group (n = 67)
Number of subjects: 123
Study: 7988320

Group type: EXPERIMENTAL
Intervention: Sustacal administration
Number of subjects: 19
Study: 2567127

Group type: EXPERIMENTAL
Intervention: Flumazenil (Group F)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Group C)
Number of subjects: 40
Study: 31157819

Group type: EXPERIMENTAL
Intervention: CJR model (treatment)
Number of subjects: 157828

Group type: COMPARATOR
Intervention: non-CJR model (control)
Number of subjects: 157828
Study: 28061851

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment (IPT) for malaria in schoolchildren (IPTsc)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Training for school staff to administer IPT
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Preference for health workers over teachers for drug administration
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Diagnosis of malaria infection before IPT administration
Number of subjects: 86
Study: 26418868

Group type: EXPERIMENTAL
Intervention: McKenzie method and Muscle Energy Technique (MET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: McKenzie method alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 60
Study: 23499604

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) influenza vaccine (Fluzone(®) Intradermal) 9μg HA per strain in 0.1mL
Number of subjects: 4292

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) influenza vaccine
Number of subjects: 4292

Group type: COMPARATOR
Intervention: Intramuscular (IM) influenza vaccine (standard dose) 15μg HA per strain in 0.5mL
Number of subjects: 4292

Group type: COMPARATOR
Intervention: Intramuscular (IM) influenza vaccine (standard dose)
Number of subjects: 4292
Study: 22110169

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (EPA, DHA, ALA)
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1014
Study: 19767793

Group type: EXPERIMENTAL
Intervention: High-CHO energy-restricted diet (low fat)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low-CHO energy-restricted diet (high fat)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Physical activity (measured with a triaxial accelerometer and questionnaire)
Number of subjects: 40
Study: 17965792

Group type: EXPERIMENTAL
Intervention: Dietary intervention (1200-1400 kcal/day diet with 25% proteins, 25% fat, 50% carbohydrates plus 25-30 gm of fiber per week)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Metformin (850 mg twice daily)
Number of subjects: 46
Study: 15257499

Group type: EXPERIMENTAL
Intervention: Stapler haemorrhoidectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional haemorrhoidectomy (control group)
Number of subjects: 80
Study: 12149103

Group type: EXPERIMENTAL
Intervention: Enalapril (mean dose 17 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Losartan (mean dose 77 mg/day)
Number of subjects: 32
Study: 9794859

Group type: EXPERIMENTAL
Intervention: Routine care plus additional training for doctors and nurses (1.5 days' group training)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 250
Study: 8083697

Group type: EXPERIMENTAL
Intervention: Vinorelbine 100 mg/m2 orally
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m2 intravenously (IV)
Number of subjects: 17
Study: 2666482

Group type: EXPERIMENTAL
Intervention: 1000 mg of ACETM
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Desensitization to ASA followed by rechallenge with 1000 mg of ACETM
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Desensitization to increasing doses of ACETM
Number of subjects: 3
Study: 589351

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 216

Group type: COMPARATOR
Intervention: Chlorpropamide
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Both Metformin and Chlorpropamide
Number of subjects: 216
Study: 31526852

Group type: EXPERIMENTAL
Intervention: Previous night's nonrestorative sleep
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Morning pain catastrophizing
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Greater nonrestorative sleep and higher morning pain catastrophizing
Number of subjects: 220
Study: 31733362

Group type: EXPERIMENTAL
Intervention: Higher priced placebo cream
Number of subjects: 19

Group type: COMPARATOR
Intervention: Lower priced placebo cream
Number of subjects: 19
Study: 30077564

Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring with pharmacist case management
Number of subjects: 228
Study: 26360148

Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 1 ml at a concentration of 0.5%
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both groups (MB and control)
Number of subjects: 115
Study: 25399274

Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure with the device (n=463)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Warfarin (n=244; target INR 2-3)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Warfarin (n=244)
Number of subjects: 707
Study: 22539536

Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation protocol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional rehabilitation protocol
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 20461008

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoniazid, rifampicin, pyrazinamide, and ethambutol
Number of subjects: 60
Study: 17564692

Group type: EXPERIMENTAL
Intervention: Instructional DVD (10 min)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Traditional face-to-face teaching (20 min)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 15764752

Group type: EXPERIMENTAL
Intervention: Third-generation agents (e.g., gemcitabine, taxanes, vinorelbine)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Best supportive care
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Platinum plus a third-generation drug
Number of subjects: 230
Study: 11996639

Group type: EXPERIMENTAL
Intervention: Trizivir (zidovudine, lamivudine, abacavir), dosing schedule of one pill twice-daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protease inhibitor-based regimens (e.g., indinavir)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trizivir
Number of subjects: 0
Study: 9918268

Group type: EXPERIMENTAL
Intervention: Biochemical markers and BMD
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Bone Mineral Density (BMD)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Vertebral fractures
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Height
Number of subjects: 74
Study: 7493436

Group type: EXPERIMENTAL
Intervention: Octreotide (subcutaneous)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 18
Study: 2034777

Group type: EXPERIMENTAL
Intervention: Structured guidance intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 16435478

Group type: EXPERIMENTAL
Intervention: Surgical treatment for duodenal ulcer
Number of subjects: 88
Study: 31093681

Group type: EXPERIMENTAL
Intervention: health advice + app
Number of subjects: 110

Group type: COMPARATOR
Intervention: health advice
Number of subjects: 110
Study: 28982352

Group type: EXPERIMENTAL
Intervention: Secondary closure (SC) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary closure (PC) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Membrane based primary closure (MBPC) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 26426863

Group type: EXPERIMENTAL
Intervention: BCG vaccination with scar
Number of subjects: 3801

Group type: EXPERIMENTAL
Intervention: BCG vaccination with positive TST response
Number of subjects: 3801

Group type: EXPERIMENTAL
Intervention: BCG vaccination with both scar and positive TST
Number of subjects: 3801

Group type: EXPERIMENTAL
Intervention: BCG vaccination with scar and positive TST
Number of subjects: 3801
Study: 25015354

Group type: EXPERIMENTAL
Intervention: 30 mg/kg/d DHA
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo plus daily multivitamin
Number of subjects: 78
Study: 23031506

Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Parkinson's disease
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy older adults
Number of subjects: 59
Study: 20085600

Group type: EXPERIMENTAL
Intervention: Birch pollen extract
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 17516397

Group type: EXPERIMENTAL
Intervention: Imiquimod 7.5% cream administered topically every other day for 20 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intravenous meglumine antimoniate administered at a dosage of 20 mg/kg per day every day for 20 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination therapy with intravenous meglumine antimoniate and imiquimod 7.5% cream
Number of subjects: 21
Study: 15366587

Group type: EXPERIMENTAL
Intervention: Yigu capsule (YGC)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Osteocalcin capsule
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 210
Study: 11422018

Group type: EXPERIMENTAL
Intervention: Nadolol (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9722128

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propanolol (20 mg/day and 40 mg during the menstrual period)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg/day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pyridoxine (300 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 7740595

Group type: EXPERIMENTAL
Intervention: Interpersonal problem-solving skills training (IPSST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control treatment condition (brief problem-oriented approach)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: IPSST
Number of subjects: 39
Study: 3259170

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine, 30 mg intramuscularly four times a day for 5 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo, two capsules orally four times a day for the last 2 study days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aspirin, two 325 mg capsules orally four times a day for the same schedule
Number of subjects: 26
Study: 29573863

Group type: EXPERIMENTAL
Intervention: Optive Fusion (OF) - carmellose 0.5% and hyaluronic acid 0.1%
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Optive Fusion (OF)
Number of subjects: 19
Study: 28460284

Group type: EXPERIMENTAL
Intervention: FAR intervention (training to recognize emotional information, conveyed by changes in facial features)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Attention-to-facial-features intervention (training to detect changes in facial features)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 39
Study: 25416642

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin (OT)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 20 IU intranasal vasopressin (AVP)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 22390550

Group type: EXPERIMENTAL
Intervention: Gingival unit grafts (n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Palatal grafts (n = 9)
Number of subjects: 17
Study: 16724185

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone at 30 mg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Higher doses of oral micronized progesterone (60 mg/day and 200 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43